| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.74▲ | 6.79▲ | 6.77▲ | 6.37▲ | 6.75▲ |
| MA10 | 6.72▲ | 6.74▲ | 6.58▲ | 6.39▲ | 7.68▼ |
| MA20 | 6.76▲ | 6.54▲ | 6.38▲ | 6.73▲ | 8.29▼ |
| MA50 | 6.75▲ | 6.35▲ | 6.31▲ | 8.07▼ | 7.40▼ |
| MA100 | 6.62▲ | 6.31▲ | 6.48▲ | 8.45▼ | 6.36▲ |
| MA200 | 6.40▲ | 6.53▲ | 7.04▼ | 7.62▼ | 7.90▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.014▲ | 0.061▲ | 0.077▲ | -0.395▼ |
| RSI | 55.797▲ | 61.768▲ | 66.161▲ | 47.305▼ | 45.141▼ |
| STOCH | 46.785 | 70.105 | 73.742 | 33.184 | 8.594▼ |
| WILL %R | -34.286 | -22.436▲ | -20.115▲ | -23.529▲ | -83.788▼ |
| CCI | 49.264 | 47.589 | 74.836 | 105.309▲ | -94.412 |
|
Wednesday, February 04, 2026 04:56 AM
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced preliminary, unaudited fourth ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 04/02/26 | 6.42 | 7.00 | 6.42 | 6.79 | 4,782,901 |
| 03/02/26 | 6.20 | 6.38 | 6.10 | 6.30 | 1,036,200 |
| 02/02/26 | 6.032 | 6.25 | 6.01 | 6.25 | 1,208,229 |
| 30/01/26 | 6.38 | 6.44 | 6.08 | 6.10 | 1,482,300 |
| 29/01/26 | 6.21 | 6.48 | 6.15 | 6.41 | 1,271,700 |
| 28/01/26 | 6.49 | 6.50 | 6.105 | 6.23 | 1,290,678 |
| 27/01/26 | 6.23 | 6.53 | 6.19 | 6.50 | 1,215,450 |
| 26/01/26 | 6.30 | 6.48 | 6.14 | 6.24 | 1,546,900 |
| 23/01/26 | 6.67 | 6.7468 | 6.355 | 6.38 | 1,973,637 |
| 22/01/26 | 6.40 | 6.78 | 6.33 | 6.69 | 2,441,860 |
|
|
||||
|
|
||||
|
|